TAILORx shows that clinical risk features alone are not sufficient to determine chemotherapy benefit.
73% of patients with high clinical risk* had Recurrence Score results 0-25 and may have been overtreated without the Recurrence Score result**
*High clinical risk: Grade 1, >3 cm; Grade 2, >2 cm; Grade 3, >1 cm.
**Based on the primary analysis of TAILORx study
43% of patients with Recurrence Score results 26-100 had low clinical risk*** and may have been undertreated without the Recurrence Score result
***Low clinical risk: Grade 1, ≤3 cm; Grade 2, ≤2 cm; Grade 3, ≤1 cm.